Reasons Why Long-term Faith on TG Therapeutics Inc. (TGTX) Could Pay Off Investors

Let’s start up with the current stock price of TG Therapeutics Inc. (TGTX), which is $24.81 to be very precise. The Stock rose vividly during the last session to $25.02 after opening rate of $24.73 while the lowest price it went was recorded $24.03 before closing at $24.50.

Recently in News on August 13, 2020, TG Therapeutics Announces FDA Acceptance of New Drug Application for Umbralisib as a Treatment for Patients with Previously Treated Marginal Zone Lymphoma and Follicular Lymphoma. TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for umbralisib, the Company’s investigational once-daily, oral, dual inhibitor of PI3K-delta and CK1-epsilon, as a treatment for patients with previously treated marginal zone lymphoma (MZL) who have received at least one prior anti-CD20 based regimen and follicular lymphoma (FL) who have received at least two prior systemic therapies. The MZL indication, under Breakthrough Therapy Designation (BTD), has been accepted for Priority Review and has a Prescription Drug User Fee Act (PDUFA) goal date of February 15, 2021. The FL indication has been accepted for standard review with a PDUFA goal date of June 15, 2021. The FDA also notified the Company that it is not currently planning to hold an advisory committee meeting to discuss this application. You can read further details here

TG Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $25.02 on 08/31/20, with the lowest value was $6.34 for the same time period, recorded on 03/18/20.

TG Therapeutics Inc. (TGTX) full year performance was 299.44%

Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, TG Therapeutics Inc. shares are logging -0.54% during the 52-week period from high price, and 401.11% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $4.95 and $24.94.

The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1636055 for the day, which was evidently lower, when compared to the average daily volumes of the shares.

When it comes to the year-to-date metrics, the TG Therapeutics Inc. (TGTX) recorded performance in the market was 123.47%, having the revenues showcasing 32.43% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 3.11B, as it employees total of 176 workers.

Specialists analysis on TG Therapeutics Inc. (TGTX)

During the last month, 0 analysts gave the TG Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.

According to the data provided on, the moving average of the company in the 100-day period was set at 18.99, with a change in the price was noted +14.70. In a similar fashion, TG Therapeutics Inc. posted a movement of +145.59% for the period of last 100 days, recording 2,002,850 in trading volumes.

Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for TGTX is recording 0.15 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.11.

Trends and Technical analysis: TG Therapeutics Inc. (TGTX)

Raw Stochastic average of TG Therapeutics Inc. in the period of last 50 days is set at 97.07%. The result represents improvement in oppose to Raw Stochastic average for the period of the last 20 days, recording 97.07%. In the last 20 days, the company’s Stochastic %K was 96.46% and its Stochastic %D was recorded 95.42%.

Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 123.47%. Additionally, trading for the stock in the period of the last six months notably improved by 83.47%, alongside a boost of 299.44% for the period of the last 12 months. The shares increased approximately by 7.29% in the 7-day charts and went down by 26.69% in the period of the last 30 days. Common stock shares were driven by 32.43% during last recorded quarter.